Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Allogene Therapeutics Inc 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 USA

www.allogene.com Employees: 229 P: 650-457-2700

Sector:

Medical

Description:

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.'

Key Statistics

Overview:

Market Capitalization, $K 379,794
Enterprise Value, $K 304,574
Shares Outstanding, K 224,730
Float, K 195,066
% Float 86.80%
Short Interest, K 18,633
Short Float 8.29%
Days to Cover 3.51
Short Volume Ratio 0.31
% of Insider Shareholders 13.20%
% of Institutional Shareholders 83.63%

Financials:

Annual Sales, $ 20 K
Annual Net Income, $ -257,590 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -41,400 K
EBIT, $ -227,400 K
EBITDA, $ -222,110 K

Growth:

1-Year Return 17.86%
3-Year Return -76.53%
5-Year Return -95.13%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 32.24%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.19 on 11/06/25
Next Earnings Date 03/12/26
Earnings Per Share ttm -0.98
EPS Growth vs. Prev Qtr 17.39%
EPS Growth vs. Prev Year 29.63%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ALLO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -57.79%
Return-on-Assets % -43.11%
Profit Margin % -1,287,950.01%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.19
Book Value/Share 1.42
Interest Coverage -1,427.61
60-Month Beta 0.60
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar